Inside Innovation

Bristol Myers Squibb reported phase 3 results showing that its bispecific antibody-drug conjugate izalontamab brengitecan significantly improved survival outcomes for previously treated triple-negative breast cancer

Philips plans to put its longtime Bothell campus up for sale as part of a long-term real estate strategy while maintaining its healthcare operations and

The Allen Institute has launched the Brain Health Accelerator, a new $400 million initiative aimed at developing gene therapies for neurodegenerative diseases including Alzheimer’s, Parkinson’s,

GEN’s annual ranking of the top U.S. biopharma clusters highlights the regions leading the nation in life sciences competitiveness, with Seattle ranked No. 10 overall

Aptevo Therapeutics, a Seattle-based clinical-stage biotechnology company, has received a $500,000 investment from Niowave, a Michigan-based medical radioisotopes company, as part of a collaboration to

Seattle-based AGC Biologics has been selected by Japanese pharmaceutical company Teikoku Seiyaku to provide microbial contract development and manufacturing services for KTP-001, a recombinant human

The Pacific Northwest is rapidly advancing as a center for AI-driven drug discovery through coordinated federal initiatives, startup investment, and expanding research infrastructure across Seattle,

Anthropic and the Gates Foundation have launched a four-year, $200 million partnership to support artificial intelligence initiatives focused on global health, education, and public-interest research.

Life sciences and health innovation companies were among the organizations recognized at the 2026 GeekWire Awards, highlighting the growing influence of Washington’s biotech, healthcare, and

A new editorial highlights Spokane’s rapid emergence as a major contributor to Washington’s expanding life sciences industry. The article points to recent investments including new

AGC Biologics received the 2026 Fierce Outsourcing Award for Leadership in Regulatory and Quality Compliance in recognition of its regulatory strategy, quality systems, and compliance

Fred Hutch Cancer Center researchers published a large-scale study showing that many FDA-approved kinase inhibitors can effectively target additional cancer-driving mutations beyond their original intended